BUZZ--美国股票走势-特斯拉、星座品牌、KalVista 制药公司

路透中文
Jul 07, 2025
BUZZ--美国股票走势-特斯拉、<a href="https://laohu8.com/S/STZ">星座品牌</a>、KalVista 制药公司

个股走势的 Eikon 搜索字符串:STXBZ

The Day Ahead时事通讯:https://refini.tv/3LI4BU7

新闻早报》通讯:https://refini.tv/3dKUyB8

7月7日 - 美国股指期货周一下滑,投资者正努力应对围绕美国关税政策的不确定性 (link),而特斯拉股价在首席执行官马斯克(Elon Musk)宣布计划组建政党后下跌。 .N

** Tesla Inc < TSLA.O (link) >:BUZZ - 马斯克的政治举动令投资者动摇,股价下滑 nL4N3T40GA

** Netflix Inc < NFLX.O (link) >:BUZZ - Seaport 将 Netflix 的评级下调至 "中性";股价下跌。 nL6N3T408Y

** WNS Holdings Ltd < WNS.N (link) >:BUZZ - Capgemini下跌,因为WNS交易引发了对人工智能商业影响的质疑。 nL8N3T40EI

** 纽蒙特公司 < NEM.N (link) >:

** 巴里克矿业公司 < B.N (link) >:

** Gold Fields Ltd < GFI.N (link) >:

** AngloGold Ashanti PLC < AU.N (link) >:

BUZZ - 金矿商下跌,金银价格因美元走强而走低 nL4N3T40KT

** CrowdStrike Holdings Inc < CRWD.O (link) >:BUZZ - Piper Sandler下调CrowdStrike评级至 "中性";股价下跌 nL6N3T40AV

** Constellation Brands Inc < STZ.N (link) >:BUZZ - Jefferies 将其评级升至 "买入",股价上涨。 nL6N3T40B0

** Apogee Therapeutics Inc < APGE.O (link) >:BUZZ - 因湿疹药物在中期研究中达到主要目标而跳涨 nL4N3T40N1

** KalVista Pharmaceuticals Inc < KALV.O (link) >:BUZZ - 因肿胀障碍药物获得 FDA 批准而上涨 nL4N3T40O4

** Molina Healthcare Inc < MOH.N (link) >:BUZZ - 因下调年度利润预期而下跌 nL4N3T40OD

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10